shares in this article
ETFs in this article
DThe disturbing news about the sharp rise in corona cases in China has caused shares in BioNTech and Moderna to rise sharply. Valneva also went up significantly.
The jumps in prices could not be explained rationally, because China urgently needed more effective vaccines, but that Beijing would fall back on BioNTech or even Moderna seems rather unlikely, at least for the time being. After all, BioNTech has long had a partnership with Fosun Pharma to distribute the Corminaty vaccine in China. But the government is apparently delaying approval because of the preference given to vaccines developed at home. In the meantime, mRNA variants are also said to be about to be approved there.
The possibility that the number of cases could soon increase again in the USA, as in some European countries including Germany, seems more tangible. Effluent analyzes from the US East Coast indicate that the cause could be the omicron variant BA.2. BioNTech and Pfizer have filed for US approval of a fourth dose. Another wave of infections should boost demand. In addition, the titles are considered a hedge against another corona crash.
Notice of Conflicts of Interest:
The majority owner of the sole shareholder of Finanzen Verlag GmbH, Mr. Bernd Frtsch, has taken direct and indirect positions on the following financial instruments mentioned in the publication or related derivatives that can benefit from any price development resulting from the publication: BioNTech, Curevac, GlaxoSmithKline , Novavax, Pfizer, Valneva.
INVESTOR INFO
A double-digit percentage gain since the recommendation last week – the shares of the French-Austrian vaccine manufacturer have developed a clear upward trend. Valneva’s Covid vaccine made from inactivated viruses and Dynavax’s adjuvant should soon be approved in the EU. With the number of cases rising, the commercial prospects for the vaccine are broadening as renewed booster rounds are becoming more likely at the moment. In addition, there are the two attractive product candidates for the prevention of Chikungunya and Lyme disease. Risk-taking investors step in.
The Nasdaq Biotechnology Index, one of the most important industry barometers, is deep red this year. The mood is now so bad that investors are already cheering that biotech IPOs in 2022 will possibly bring in as little money as they did last time in 2013. Because that could be an indication of a cleansing and renewal. Hardened countercyclical investors use the low prices to get started. The ETF tracks the development of almost 400 biotech and pharmaceutical companies listed on the US technology exchange. Of the well-known vaccine stocks, Moderna is represented with just over four percent.
Leverage must be between 2 and 20
No data
More news about BioNTech (ADRs)
Image sources: Thomas Lohnes/Getty Images, Ascannio / Shutterstock.com, Finanzen Verlag
ttn-28